Vaccination with irradiated granulocyte macrophage-colony stimulating factor (GM-CSF)-transduced autologous tumor cells (GVAX) has been shown to induce therapeutic antitumor immunity. However, its effectiveness is limited. We therefore attempted to improve the antitumor effect by identifying little known key pathways in GM-CSF-sensitized dendritic cells (GM-DCs) in tumor-draining lymph nodes (TDLNs).
Introduction
In recent clinical trials of patients with diverse solid cancers, cancer immunotherapy such as therapeutic vaccination with granulocyte-macrophage colony stimulating factor (GM-CSF) gene-transduced tumor vaccines (GVAX) as well as sipuleucel-T (Provenge ® ), the first US FDA-approved GM-CSF-based therapeutic dendritic cell vaccine for prostate cancer, induced antitumor immune responses with tolerability(1-3).
However, the efficacy of this therapy alone is not satisfactory, raising an urgent need to improve the antitumor effect of GVAX. Although GM-CSF signaling is essential in conventional dendritic cells (cDCs) maturation, and which leads to effective generation of tumor-associated antigen (TAA)-specific T cells and differentiation, the underlying molecular mechanism of how GM-CSF sensitizes and matures DCs (GM-DCs) to trigger host antitumor immunity remains unclear.
Therefore, in this study, we attempted to improve the antitumor effects of GVAX therapy through the identification of the key cluster genes upregulated in GM-DCs that operate T cell priming in tumor draining lymph nodes (TDLNs) by conducting a cDNA microarray analysis. We used a syngeneic Lewis lung carcinoma (LLC)-bearing mouse,
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Materials and Methods
Mice
Five-to ten-week-old female immunocompetent C57/BL6N and BALB/cN mice were purchased from Charles River Japan (Tokyo, Japan) and housed in the animal maintenance facility at Kyushu University. Type I IFN receptor knockout (IFNAR were performed. Both of LLC cells and CT26 cells were validated as free from mycoplasma infection; no other validations were performed besides the former were found as free from ectromelia virus. LLC and B16F10 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM, Nakalai Tesque, Kyoto, Japan) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% antibiotic mixture (Nakalai Tesque). CT26 was maintained in RPMI 1640 (Nakalai Tesque) supplemented with 10% FBS and 1% antibiotic mixture.
Gene transduction with non-transmissible recombinant Sendai virus vectors
LLC, B16F10 or CT26 cells were infected with non-transmissible Sendai virus vectors encoding GFP (green fluorescence protein) or mouse GM-CSF (SeV/GFP or SeV/GM, respectively), which were prepared by DNAVEC Corp. (Tsukuba, Japan) (6) , at the indicated multiplicity of infection (MOI) for 90 min (named as LLC/SeV/GFP, LLC/SeV/GM, B16/SeV/GFP, B16/SeV/GM or CT26/SeV/GM cells, respectively).
They were cultured for 48 hours after viral gene transduction and used for following mouse studies.
In vivo experiments
For tumorigenicity assays, syngeneic C57/BL6N mice were s.c. challenged with 2.0 × 
ELISA assay
In vitro expression levels of mouse GM-CSF produced from LLC, LLC/SeV/GFP, or LLC/SeV/GM cells at the MOI and time points, were measured using mouse GM-CSF enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN).
Flow cytometric analysis
TDLNs, spleen and tumor vaccine site (TVS) harvested from the indicated groups of mice (n=3-5) were homogenized and filtered through a 100 µm cell strainer (BD Biosciences, San Jose, CA). For splenocytes preparation, smashed spleens were treated with ammonium chloride to lyse red blood. For T cell detection in mixed lymphocyte reaction (MLR) assays, cells were stained with anti-CD4 (RM4. 
Allogeneic MLR assays
To prepare CD11c + DCs as stimulators, on day 2 of the tumorigenicity assay, CD11c subset as stimulators, total bone marrow cells harvested from naïve C57/BL6N mice were cultured in RPMI1640 supplemented with 50 ng/ml murine Fms-related tyrosine kinase 3 ligand (Flt3L; PeproTech, Rocky Hill, NJ) for 8 days and Siglec-H positive cells (pDCs) were purified using anti-Siglec-H-FITC antibody and anti-FITC MicroBeads (Miltenyi Biotec). Sorted pDCs were then incubated overnight with or without 2.5 µg/ml imiquimod or 10 ng/ml murine recombinant GM-CSF (PeproTech).
To prepare allogeneic T cells as responders, T cells were sorted from splenocytes harvested from naïve BALB/cN mice using a Pan T cell isolation kit II (Miltenyi Microarray data were deposited in Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) (accession number GSE43169).
In vivo depletion experiments
To deplete pDCs, mice were injected intraperitoneally (i.p.) with 100 µg of Immunoresearch, West Grove, PA) as previously described (7) . Effective depletion of PDCA-1 + cells was confirmed by flow cytometric analysis ( Supplementary Fig. S1 ).
CD4
+ T or CD8 + T cells were depleted by using GK1.5 or 2.43 mAbs as previously described (8 
Results
Production of GM-CSF from LLC and B16F10 cells remarkably impaired the tumorigenicity
To test the possibility that substantial secretion of GM-CSF from syngeneic mouse cancer cells facilitates the development of antitumor immune responses, we used recombinant non-transmissible Sendai virus vectors expressing GM-CSF (SeV/GM) at various MOI. Abundant GM-CSF production from the infected LLC (LLC/SeV/GM) cells was observed and was MOI dependent (Fig. 1A) . The proliferation rate of LLC cells was not affected by transduction with SeV/GM as previously described (6) . We next performed tumorigenicity assays in which each LLC and LLC/SeV/GM cells (MOI=1, 10 and 100) were s.c. injected into the left flank of syngeneic mice. All mice treated with LLC/SeV/GM cells exhibited significant suppression of the tumor outgrowth in a MOI-dependent manner (Fig. 1B) . We thus determined MOI=100 for gene transduction as an optimized infection dose. Notably, mice treated with LLC/SeV/GM cells significantly suppressed tumor growth and prolonged the survival of mice, compared with control groups (P < 0.001) ( tumor growth and prolongation of mouse survival were observed when SeV/GM-infected B16F10 melanoma cells were injected to C57BL/6N mice (Fig. 1D ). expressed between GM-DCs and GFP-DCs with statistical significance (upregulated genes; Z-score ≥2 and ratio >1.5, downregulated genes; Z-score ≤-2 and ratio <0.66) (data not shown). A list of the genes significantly upregulated in the top ten canonical pathways in CD86 + GM-DCs in comparison with CD86 + GFP-DCs is shown in Table 1 .
Increased ability of GM-CSF-sensitized
As expected, these genes composed immunological responses-related pathways ( GM-CSF-sensitized DCs/T cell priming (11) . Indeed, the number of pDCs, CD11b + cDCs and CD8 + cDCs subsets from total GM-DCs from TDLNs harvested on days 2 and 4 were greater than the equivalent subsets from total GFP-DCs (Fig. 3D) .
Furthermore, the results of in vivo experiments using IFN-α receptor knockout (Fig. 3E) . Importantly, similar results were also obtained when pDCs-depleted mice were used (Fig. 3F) . These results collectively demonstrate the positive role of type I IFN-producing pDCs in the induction of GM-CSF-mediated antitumor immunity. 
Combination of TLR7 ligand and GM-CSF-secreting LLC
proliferation capacity of pDCs, we performed an allogeneic MLR assay. pDCs stimulated with GM-CSF and imiquimod elicited the most pronounced proliferative activity of CD8 + T cells, but not CD4 + T cells, when compared with controls (Fig. 5F ).
Moreover, the synergistic therapeutic efficacy of irLLC/SeV/GM cells and imiquimod was significantly inhibited when the corresponding mice were depleted of CD4 + or CD8 + T cells (Fig. 5G) . 
Discussion
The present study demonstrates that SeV/dF-mediated exogenous expression of GM-CSF caused poor growth of cancer cells in syngeneic mice, concomitant with an early appearance of mature DCs in TDLNs. We used SeV/dF vectors for the gene transduction of vaccine cells because they have relatively higher capacities in terms of gene transduction, induction of antitumor immunity and safety (6, 15) . Expression microarray analyses of the GM-CSF-sensitized CD86 + DCs revealed increased expression of the TLR7-IRF7 pathway components, which induce type I IFN production in pDCs (5) . Furthermore, the addition of imiquimod was found to be an effective potential approach to improve the antitumor effects of GVAX therapy (Fig. 4) .
As LLC cells has been considered a poorly immunogenic lung cancer (16) , it was surprising that tumor challenge with LLC/SeV/GM cells markedly impaired its tumorigenicity with complete tumor disappearance in half of mice tested (Fig. 1) .
Additionally, mice that received prophylactic vaccination with irLLC/SeV/GM cells also significantly inhibited subsequent tumor challenge with LLC cells ( Supplementary   Fig. S6 ). However, therapeutic vaccination using irLLC/SeV/GM cells alone failed to (Fig. 4C) . We therefore attempted to potentiate the therapeutic antitumor effects of irLLC/SeV/GM cells through scrutinizing the gene expression signature of GM-CSF-sensitized DCs in TDLNs from mice that strongly rejected the tumor challenge with LLC/SeV/GM cells. We confirmed that GM-CSF facilitated the maturation of DCs into antigen-presenting cells (APCs) with enhanced ability to prime naïve T cells to proliferate, and to increase expression of CD80, CD86, MHC class I, MHC class II, and CD40 ( Fig. 2B and Supplementary Fig. S7 ), consistent with previous finding that GM-CSF promotes DCs maturation and differentiation (17) .
Herein transcriptome analyses revealed that GM-CSF also modulated signal transduction in pDCs by upregulation of the TLR7-IRF7 pathway related to type I IFN production (Fig. 3) , consistent with a previous report where GM-CSF stimulation upregulated TLR7 expression in mouse immune cells (18) . Our observation that the pDC subset was markedly increased in GM-DCs from TDLNs was unexpected, as the signaling on the effective generation of GM-CSF-induced antitumor immunity ( Fig. 3E and 3F). Thus, there may be a functional dichotomy in pDCs biology between immune tolerance and antitumor phenotype where their redirection is dependent on the tumor microenvironment.
Imiquimod, TLR7 ligand, could be regarded as the most effective adjuvant among all approved immunomodulators based on the following: 1) topical imiquimod is currently FDA approved with a good safety profile, 2) it potently activates APCs to release type I IFN and Th1-skewing cytokines, and 3) imiquimod treatment leads to CCL2-dependent recruitment of pDCs and their transformation into killer DCs (37) . The underlying mechanism of substantial antitumor efficacy by the combined vaccination may be due to generation of functionally mature pDCs in TVS and TDLNs ( Fig. 5A and Supplementary Fig. S4 ). IFN-α, mainly produced from pDCs upon exposure to viruses via TLR7 or TLR9 (38) , acts directly on memory T cells, which potentiate the antigen presentation and cross-priming capacities of CD11b + cDCs (39, 40) . We detected CD9 + pDCs, which produce abundant IFN-α (14), in TDLNs from mice injected with ir.LLC/SeV/GM cells ( Fig. 5C and 5D ). of our findings (Fig. 4C and 4D ).
In conclusion, we for the first time elucidated that the beneficial roles of the pDCs and relevant type I-IFN pathway in GM-CSF-induced antitumor immunity and that the combinational use of imiquimod with GVAX therapy produced synergistic antitumor effects, underscoring its potential as a promising approach for the treatment of cancer. 
